骨髓发育异常相关基因突变与急性髓系白血病起源的交互作用
该研究对在纪念斯隆凯特琳癌症中心治疗的344例新诊断急性髓系白血病(AML)患者进行详细注释,发现基于数据库登记的起源判定缺乏准确性,骨髓发育异常相关(MR)基因突变常见于新发AML;仅EZH2和SF3B1突变在单因素分析中与较差结局相关,多因素分析中AML起源具有独立预后价值,且新发AML伴MR基因突变未显示不良结局,研究对当前AML伴MR基因突变的分类和风险分层提出质疑。
要点
- 基于数据库登记的AML起源判定缺乏准确性。
- MR基因突变常见于新发AML,仅EZH2和SF3B1突变在单因素分析中与较差结局相关。
- 新发AML伴MR基因突变未显示不良结局,研究对当前分类和风险分层提出质疑。
核心结论
- 研究强调临床研究中准确判定AML起源的重要性,证明AML起源具有独立预后价值,并对当前AML伴MR基因突变的分类和风险分层提出质疑。
研究设计与样本
- 对在纪念斯隆凯特琳癌症中心治疗的344例新诊断AML患者队列进行详细注释。
主要发现
- 基于数据库登记的起源判定缺乏准确性。
- MR基因突变常见于新发AML。
- 单因素分析中,MR基因突变中仅EZH2和SF3B1与较差结局相关。
- 多因素分析中,即使调整年龄、治疗、异基因移植和基因组类别或ELN风险后,AML起源仍具有独立预后价值。
- 起源也有助于对伴MR基因突变的AML进行结局分层。
关键数值与推荐
- 世界卫生组织(WHO)和国际共识分类将MR基因突变列为AML-MR的诊断标准之一,主要基于这些突变对伴前驱骨髓发育异常综合征的AML具有特异性的假设。
- 国际共识分类(ICC)将MR基因突变优先于起源(如临床病史所定义)。
- 欧洲白血病网(ELN)2022将这些MR基因突变分层为不良风险组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate classification and risk stratification are critical for clinical decision making in patients with acute myeloid leukemia (AML). In the newly proposed World Health Organization and International Consensus classifications of hematolymphoid neoplasms, the presence of myelodysplasia-related (MR) gene mutations is included as 1 of the diagnostic criteria for AML, AML-MR, based largely on the assumption that these mutations are specific for AML with an antecedent myelodysplastic syndrome. ICC also prioritizes MR gene mutations over ontogeny (as defined in the clinical history). Furthermore, European LeukemiaNet (ELN) 2022 stratifies these MR gene mutations into the adverse-risk group. By thoroughly annotating a cohort of 344 newly diagnosed patients with AML treated at the Memorial Sloan Kettering Cancer Center, we show that ontogeny assignments based on the database registry lack accuracy. MR gene mutations are frequently observed in de novo AML. Among the MR gene mutations, only EZH2 and SF3B1 were associated with an inferior outcome in the univariate analysis. In a multivariate analysis, AML ontogeny had independent prognostic values even after adjusting for age, treatment, allo-transplant and genomic classes or ELN risks. Ontogeny also helped stratify the outcome of AML with MR gene mutations. Finally, de novo AML with MR gene mutations did not show an adverse outcome. In summary, our study emphasizes the importance of accurate ontogeny designation in clinical studies, demonstrates the independent prognostic value of AML ontogeny, and questions the current classification and risk stratification of AML with MR gene mutations.
引用
- McCarter JGW, Nemirovsky D, Famulare CA, et al. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv. 2023. PMID: 37142255. doi:10.1182/bloodadvances.2023009675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。